There are certain factors that investors look into when they try to discover new stocks to track. One such factor is momentum. Stocks with strong momentum can often deliver handsome gains if they continue on the same track. Here is a quick look at four penny stocks that have gained momentum recently and could be worthy additions to any investor’s watchlist.
Ameritek Ventures Inc. (OTC:ATVK) is seeing positive momentum in the market as it makes the right steps in its bid to become a leading provider of robotic technology. The company has rekindled market interest, as evidenced by a high turnover in traded shares, indicating that investors are taking notice of its prospects as a leading provider of artificial intelligence software, blockchain cloud software, and, most importantly, robotic technology.
A confirmation on September 7, 2023, that the company has filed a new patent for robotic arm technology is the latest development triggering positive momentum in the market. Over the past four years, the company, through its subsidiary Augmum, has been working on its robotic arm technology, which continues to elicit strong interest in diverse industries.
“We are preparing the robotic arm technology for the market; it has been under development for the past 4 years,” said Shaun Passley, Ph.D., CEO of Ameritek Ventures, Inc. “Robotic Arm Technology works with our HailOas glasses to offer an all-in-one solution for remote environmental interaction.”
Consequently, it has started creating a platform that would allow operators in the military and healthcare sectors to access the technology and interact with distinct environments. The ultimate goal is to make it easy for military doctors and other healthcare providers to interact with patients in diverse environments.
The robotic arm technology for which the company has filed a patent can work with HailOas glasses to offer an all-in-one solution for remote environmental interaction. The artificial intelligence-powered glasses are designed to overlay virtual information on the physical world.
The augmented reality glasses are designed for the medical, construction, and military industries, given their ability to offer critical information to the end user. Ameritek plans to set the price of the glasses at $500 to provide an affordable way for users to enjoy an enhanced experience of the AI-integrated robotic arm technology.
The patent filing comes a month after the company made important strides in its bid to become a leading provider of enterprise software. On June 28, 2023, plans were confirmed to release business decision-making software integrated with artificial intelligence capabilities. The new software is to provide balanced scorecards, employee performance appraisals, key results, and cyber security management.
ESM Software is the company’s subsidiary behind the new software that continues to develop business strategy management solutions. The unit boasts a comprehensive program list designed to transform business plans into reality. Its primary goal is to develop solutions that improve organizational processes across various industries while conducting business strategies.
By integrating artificial intelligence capabilities, the company is enhancing the functionality and usability of its solutions. Consequently, the new business development software is designed to leverage data-driven insights and automate processes. It will also make it easy for organizations to automate processes, optimize resources, and improve outcomes.
According to CEO Shaun Passley, the new business development software is well-positioned to enhance business strategy and performance management. Integrating AI capabilities is an important milestone that should enhance its competitive advantage while offering significant benefits to users.
iQSTEL Inc. (OTC:IQST) is currently making preparations for uplisting to the NASDAQ, with a revenue projection of $120 million for the 2023 financial year. iQSTEL Inc.’s focus as a company is to serve a number of the basic needs of human beings in the modern world. It seeks to do that by making those necessary tools available to people irrespective of identity, race, gender, socioeconomic status, or religion.
On September 13, the company announced that it had successfully executed a term sheet for $10 million with LDA Capital. The signing of the term sheet was part of the company’s larger strategic goal of uplisting on the NASDAQ exchange. The company is involved in the enhanced telecom space and aims to make news, general information, and communications available to as many people as possible. In the last financial year, iQSTEL generated revenues of $93.2 million, and currently it is on track to meet its projected revenue of $120 million for the 2023 financial year.
“We greatly appreciate the confidence LDA Capital has shown in iQSTEL’s track record, management team, and business plan,” said Leandro Iglesias, CEO of iQSTEL.
LDA Capital is described as an alternative investment entity that specializes in complex transactions across borders. It is led by a capable leadership team with a proven track record of over 250 transactions in both the public and private markets. It recently entered into a new partnership, thanks to which it launched a fund worth $2 billion.
The fund is focused on making region-specific investments in high-growth companies at the pre-IPO stage and publicly listed companies. In the news release, iQSTEL noted that the term sheet was not binding on the two companies and that the investment may be made following the execution of certain definitive documents. The investment of $10 million would be made in two stages. Ahead of the NASDAQ uplisting, $5 million would be placed with the company, and in exchange, LDA Capital would be issued a 24-month bond. iQSTEL noted that it would use the capital to expand its telecom business.
Enzolytics Inc. (OTC:ENZC) is a drug development company focused on the commercialization of its monoclonal antibodies and proprietary proteins meant for providing treatment for infectious diseases.
On September 6, its fully owned subsidiary unit, Virogenetics Inc., a drug development biotech entity, made a significant announcement. It announced that, based on the number of HIV-infected people in Bulgaria, the sample size for its ITV-1 trials had been set at 60 individuals. It was further announced that R&D Services Ltd. would be in charge of the clinical trials. The efforts of R&D Services would be led by Manager of Clinical Trials Aneliya Vidinlieva, who would be assisted by the Chief Medical Officer of Design, Dr. Ivaylo Tsonev, as well as three other assistants from the University of Pharmacology. Both R&D and Virogenetics believe that the clinical trials will commence at some point towards the end of this year or early next year. The clinical trials would take place at sites across Bulgaria, and R&D Services would manage all aspects of those trials.
The clinical trials of ITV-1 would be conducted in private, public, and municipal healthcare establishments. Some of the responsibilities of R&D Services pertaining to the trial include improving the quality of the data collected during the trials, providing the necessary documents related to the initial study submission, reporting any adverse events, and pre-screening the eligible patients during the course of the initial approval or review period, among others.
Finally, R&D trials would include an immunologist’s review. The purpose of the review would be to discover any correlation between patient outcomes and a different origin of immune deficiency through the deployment of cell examination.
Aridis Pharmaceuticals Inc. (OTC:ARDS) is involved in the discovery and development of anti-infectives, which could be used for the purpose of providing treatments for viral pandemics and antimicrobial resistance (AMR). Aridis Pharmaceuticals Inc. is focused on the deployment of its APEX & Trade and MabigX & Reg proprietary technology platforms for the identification of rare, potent antibody-generating B-cells from patients who have been cured of an infection.
The company is looking to rapidly manufacture mAbs for the purpose of providing therapeutic treatment to patients suffering from critical infections. The mAbs are of human origin and hence optimized at a functional level by the natural immune system of the human body. Additionally, it also makes the mAabs fit for its functions already, and hence, the company would not need to work on further engineering work to make it fully functional.
On September 15, it emerged that Aridis Pharmaceuticals would be one of the three companies that would be featured in interviews on The RedChip Money Report. It should be noted that the show is a sponsored one that is broadcast on Bloomberg TV. The program would be telecast on Bloomberg TV on September 16 at 7 p.m. Eastern Time.
The network is available in around 73 million homes across the United States. The show is produced by RedChip Companies Inc., a global investor relations and media firm with over three decades of experience. The mantra of the company is ‘Discovering Tomorrow’s Blue Chips Today’. The show is known for providing cutting-edge commentary related to small-cap investment, reviews of financial books, interviews with analysts on Wall Street, and sponsored interviews with executives of publicly listed companies.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Ameritek Ventures Inc. to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.